Logo

Novo Nordisk's Wegovy (semaglutide) Receives CHMP's Recommendation for Approval to Treat Obesity

Share this

Novo Nordisk's Wegovy (semaglutide) Receives CHMP's Recommendation for Approval to Treat Obesity

Shots:

  • The EMA's CHMP has adopted a positive opinion recommending the marketing authorization for Wegovy in adults with obesity in chronic weight management in adults with obesity
  • The approval is based on P-IIIa (STEP) study evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with one weight-related comorbidity. The results showed 17-18% average weight loss in people without T2D @68wks. and has a safe & well-tolerated profile across the program
  • The company is expected to receive final EC marketing authorization in ~2mos  & Wegovy is expected to launch in EU by H2'22. In Jun'21, Wegovy has received the US FDA's approval & was launched in the US

 Ref: Globe Newswire | Image: Novo Nordisk

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions